| Autor: |
Lia, Farahi, Fatemeh, Ghaemimanesh, Saeideh, Milani, Seyed Mohsen, Razavi, Reza, Hadavi, Ali Ahmad, Bayat, Ali, Salimi, Mohammad Mehdi, Akhondi, Hodjattallah, Rabbani |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Iranian journal of immunology : IJI. 16(2) |
| ISSN: |
1735-367X |
| Popis: |
We have previously reported the aberrant expression of Fibromodulin (FMOD) in patients with chronic lymphocytic leukemia (CLL). Although FMOD has been considered as a cytoplasmic or secretory protein, we discovered the cell surface expression of FMOD in leukemic B cells via anchoring with glycosylphosphatidylinositol (GPI).To evaluate FMOD as a new biomarker in CLL patients in comparison with healthy individuals.A monoclonal antibody was generated against human FMOD. The cell surface expression of FMOD in 52 CLL patients and 45 healthy individuals were compared by flow cytometry. A bacterial phosphatidylinositol-specific phospholipase C (PI-PLC) was used to determine the cell surface localization of FMOD using ELISA and flow cytometry techniques. Annexin V-FITC and propidium iodide (PI) was used to detect apoptosis induction in CLL PBMCs following in vitro incubation with anti-FMOD mAb.The results demonstrated the widespread cell surface expression of GPI-anchored FMOD in CLL patients (median: 79.9 %), although healthy individuals had low FMOD expression (median: 6.2 %) (p≤0.0001). The cut-off value of FMOD expression was estimated with high sensitivity and specificity at 17.9 %. Furthermore, in vitro apoptosis induction of leukemic cells following incubation with anti-FMOD mAb showed a direct apoptosis of CLL cells (27.9%) with very low effect on healthy PBMCs (6%).The membrane-anchoring of FMOD by means of a GPI moiety in leukemic cells supports FMOD as a highly potential diagnostic and therapeutic target in CLL patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
